Table #2.

Multiple Treatment Comparison, Meta-Analysis of Pharmacotherapies

	Short-term RR (95% CI)	12-Month RR (95% CI)
Control versus
Standard nicotine patch NRT (≤ 22 mg)	1.48 (1.30 – 1.69)	1.52 (1.43 – 1.61)
High-dose nicotine patch NRT (> 22 mg)	1.69 (1.32 – 2.11)	1.73 (1.62 – 1.84)
Combination NRT	1.34 (0.96 – 1.84)	1.68 (1.30 – 2.08)
Bupropion	1.40 (1.22 – 1.60)	1.7 (1.58 – 1.83)
Varenicline	2.39 (1.96 – 2.88)	2.19 (1.94 – 2.44)
Standard-dose nicotine patch therapy (≤22 mg) versus
High-dose nicotine patch NRT (> 22 mg)	1.15 (0.91 – 1.43)	1.14 (1.07 – 1.21)
Combination NRT	0.91 (0.62 – 1.29)	1.10 (0.85 – 1.37)
Bupropion	0.94 (0.77 – 1.15)	1.12 (1.02 – 1.22)
Varenicline	1.43 (1.26 – 1.60)	1.65 (1.29 – 2.07)
High-dose nicotine patch therapy (> 22 mg) versus
Combination NRT	0.78 (0.50– 1.20)	0.97 (0.73 – 1.23)
Bupropion	0.81 (0.6 – 1.09)	0.98 (0.88 – 1.09)
Varenicline	1.47 (1.06 – 2.01)	1.29 (1.12 – 1.46)
Combination NRT versus
Bupropion	1.04 (0.72 – 1.45)	1.01 (0.79 – 1.25)
Varenicline	1.78 (1.25 – 2.41)	1.28 (1.02 – 1.53)
Bupropion versus
Varenicline	1.61 (1.32 – 1.93)	1.29 (1.12 – 1.45)

For efficacy: RRs higher than 1 favor the row-defining treatment.

Adapted with permission from: Mills et al. Annals of Medicine, 2012;4: 588–597